Resultados de la búsqueda 381-390 of 16458 for multiple sclerosis

  1. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    A Study of JNJ‐68284528 Out‐of‐Specification (OOS) for Commercial Release in Patients with Multiple Myeloma. Rochester, Minn. The purpose of this study is to ...

  2. Neurología - Ensayos clínicos - Mayo Clinic

    ... multiple myeloma. Also eligible are (11) up to 6 donors with triple negative breast cancer and (12) up to 6 donors with colorectal cancer who have no ...

  3. Hematología - Ensayos clínicos - Mayo Clinic

    Alternate Doses and Dosing Schedules of Belantamab Mafodotin for the Treatment of Triple-Class Recurrent and/or Refractory Multiple Myeloma. Jacksonville ...

  4. Mayo Clinic Neurosciences Physician Update — November 2024

    Page 1.

  5. Esclerosis lateral amiotrófica - Médicos y departamentos - Mayo Clinic

    Esta enfermedad progresiva del sistema nervioso, también conocida como enfermedad de Lou Gehrig, destruye las células nerviosas.

  6. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    A Study of JNJ‐68284528 Out‐of‐Specification (OOS) for Commercial Release in Patients with Multiple Myeloma. Rochester, Minn. The purpose of this study is to ...

  7. Mieloma múltiple - Médicos y departamentos - Mayo Clinic

    Living with mieloma múltiple? Connect with others like you for support and answers to your questions in the Blood Cancers & Disorders support group on Mayo ...

  8. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    Alternate Doses and Dosing Schedules of Belantamab Mafodotin for the Treatment of Triple-Class Recurrent and/or Refractory Multiple Myeloma. Jacksonville ...

  9. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    A Study of JNJ‐68284528 Out‐of‐Specification (OOS) for Commercial Release in Patients with Multiple Myeloma. Rochester, Minn. The purpose of this study is to ...

  10. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    Inclusion Criteria are the following: age ≥ 18, blood cancer diagnosis (including B-ALL, multiple myeloma, and lymphoma), receiving a CAR-T product, able ...